April 30, 2015 Grand Ballroom AB The Westin Boston Waterfront Boston, Massachusetts This activity is jointly provided by Global Education Group and Integritas Communications. This activity is supported by an educational grant from AstraZeneca. This event is not a part of the official Internal Medicine Meeting 2015 Education Program.
CME/MEDICAL COMMUNICATIONS INQUIRIES info@integritasgrp.com integritasgrp.com
FACULTY FACULTY
Anthony J. Lembo, MD Prerecorded Associate Professor of Medicine Director, GI Motility Laboratory Harvard Medical School Beth Israel Deaconess Medical Center Boston, Massachusetts
Brooks Cash, MD Professor of Medicine University of South Alabama Health System Digestive Health Center Mobile, Alabama
Charles E. Argoff, MD Professor of Neurology Albany Medical College Director, Comprehensive Pain Center Albany Medical Center Albany, New York
For additional CME activities log on to
3
PREAMBLE
STATEMENT OF NEED/PROGRAM OVERVIEW As many as 100 million adults in the United States suffer from chronic pain.1 Among the multitude of available treatment modalities, opioids are the cornerstone for cancer pain treatment and palliative care, and they have gained increasing acceptance as an important therapeutic option for carefully selected patients with chronic noncancer pain.2,3 Yet, opioid side effects often create significant barriers to good patient outcomes.4,5 Constipation is the most common opioid-related adverse effect, affecting up to 50% of patients on long-term therapy.6-10 Opioid-induced constipation is especially burdensome because—unlike many other adverse effects of opioids—patients do not develop tolerance to treatment-related reductions in bowel motility and increases in gastrointestinal fluid absorption.5 Clinicians must proactively consider and appropriately manage opioid-related side effects—most notably, constipation. By pre-emptively explaining the risk for opioid-induced constipation, clinicians can prepare patients to discuss changes in their bowel habits and adopt prophylactic or additional management strategies that can ease this burdensome side effect. During this Interactive Exchange™ program, expert faculty will provide practical insights into structured evaluations of bowel habits, prophylactic bowel regimens, and newer pharmacologic approaches that antagonize opioid receptor activation in the gastrointestinal tract, thereby targeting the underlying cause of opioid-induced constipation.
REFERENCES 1. Institute of Medicine. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. 2011. http://www.iom.edu/Reports/2011/Relieving-Painin-America-A-Blueprint-for-Transforming-Prevention-Care-Education-Research.aspx. Accessed March 2015. 2. Chou R, Fanciullo GJ, Fine PG, et al. J Pain. 2009;10(2):113-130. 3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Adult Cancer Pain. 2010;2010. http://www.nccn.org/professionals/physician_gls/f_ guidelines.asp. Accessed March 2015. 4. Daniell HW. Am J Med. 2007;120(9):e21. 5. McNicol E, Horowicz-Mehler N, Fisk RA, et al. J Pain. 2003;4(5):231-256. 6. Bell TJ, Panchal SJ, Miaskowski C, et al. Pain Med. 2009;10(1):35-42. 7. Cook SF, Lanza L, Zhou X, et al. Aliment Pharmacol Ther. 2008;27(12):1224-1232. 8. Panchal SJ, Muller-Schwefe P, Wurzelmann JI. Int J Clin Pract. 2007;61(7):1181-1187. 9. Villars P, Dodd M, West C, et al. J Pain Symptom Manage. 2007;33(1):67-77. 10. Benyamin R, Trescot AM, Datta S, et al. Pain Physician. 2008;11(suppl 2):S105-S120.
4
TARGET AUDIENCE The educational design of this activity addresses the needs of pain specialists and other health care providers involved in the treatment of patients with opioid-induced constipation.
EDUCATIONAL OBJECTIVES After completing this activity, the participant should be better able to: • Evaluate baseline bowel habits, risk factors for OIC development, and ongoing changes in bowel function in patients on long-term opioid therapy
PREAMBLE
• Implement a prophylactic treatment plan to address OIC concurrent with the initiation of opioid therapy • Analyze current pharmacotherapies for OIC based on mechanisms of action and data on efficacy and safety • Tailor treatment regimens for patients experiencing OIC according to symptom severity, past treatment responses, and patient preferences • Discuss the essential elements of opioid pharmacology with specific focus on the effects of opioid receptor activation in the gastrointestinal tract • Communicate with opioid-treated patients about treatment-emergent adverse events through open, patient-centered dialogue throughout the course of therapy
PROGRAM AGENDA 6:30 pm – 7:00 pm Registration, Meal, Preactivity Assessment 7:00 pm – 7:10 pm Disease Management Primer 7:10 pm – 7:55 pm Case Series in Opioid-Induced Constipation 7:55 pm – 8:15 pm Choose-a-Case 8:15 pm – 8:30 pm Postactivity Assessment and Question and Answer Session
PHYSICIAN ACCREDITATION STATEMENT This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.
For additional CME activities log on to
5
PHYSICIAN CREDIT DESIGNATION Global Education Group designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
GLOBAL CONTACT INFORMATION
PREAMBLE
For information about the accreditation of this program, please contact Global at 303-395-1782 or inquire@globaleducationgroup.com.
INSTRUCTIONS TO RECEIVE CREDIT In order to receive credit for this activity, the participant must complete the evaluation form and return to a staff member at the conclusion of the program.
FEE INFORMATION & REFUND/CANCELLATION POLICY There is no fee for this educational activity.
DISCLOSURE OF UNLABELED USE This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLOSURE OF CONFLICTS OF INTEREST Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
6
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:
Brooks Cash, MD
Speakers Bureau for AstraZeneca plc, Salix Pharmaceuticals, Inc., and Takeda Pharmaceutical Company Limited.
Charles E. Argoff, MD
PREAMBLE
Speakers Bureau for Allergan, Inc., AstraZeneca plc, Depomed Inc., Iroko Pharmaceuticals LLC, Janssen Pharmaceuticals, Inc., Millenium Laboratories, and Xenoport Inc. Grant/ Research Support from Endo Pharmaceuticals Inc., Forest Laboratories, and Eli Lilly and Company. Consultant/Independent Contractor to AstraZeneca plc, Depomed Inc., Endo Pharmaceuticals, Nektar Therapeutics, Pfizer, Inc., Xenoport Inc., and Zogenix, Inc. Stock Shareholder of Depomed Inc. and Pfizer Inc. Royalties from Elsevier B.V.
Anthony J. Lembo, MD
Consultant/Independent contractor to AstraZeneca plc, Ironwood Pharmaceuticals, Inc., Prometheus Laboratories Inc., and Salix Pharmaceuticals, Inc. Grant/Research Support from Prometheus Laboratories Inc. The planners and managers reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:
Ashley Marostica, RN, MSN Amanda Glazar, PhD Andrea Funk Rose O’Connor, PhD
Nothing to disclose Nothing to disclose Nothing to disclose Nothing to disclose
DISCLAIMER Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
For additional CME activities log on to
7
SLIDES
8
For additional CME activities log on to
SLIDES
9
SLIDES
10
For additional CME activities log on to
SLIDES
11
SLIDES
12
For additional CME activities log on to
SLIDES
13
SLIDES
14
For additional CME activities log on to
SLIDES
15
SLIDES
16
For additional CME activities log on to
SLIDES
17
SLIDES
18
For additional CME activities log on to
SLIDES
19
SLIDES
20
For additional CME activities log on to
SLIDES
21
SLIDES
22
Bristol Stool Form Scale Bristol Stool Description
Form Scale
Image
Bristol Stool Description
Form Scale
Image
Bristol Stool Form Scale
Bristol Stool Form Scale CLINICAL ASSESSMENT TOOLS Description
Description Separate hard lumps, like nuts
Bristol Stool Form Scale
Description Separate hard lumps, like nuts
Bristol StoolStool Form Scale Bristol Form Scale Description
Separate hard hard lumps, lumps, like like nuts nuts Separate
Description Separate hard lumps, like nuts Sausage-shaped but lumpy
Type
Description
Image
Image
Image Image Image
Image
Separate hard lumps, like nuts Sausage-shaped but lumpy Sausage-shaped Separate Separate hard lumps, like nuts 1but lumpy
Sausage-shaped but lumpy
hard lumps, like nuts
Sausage-shaped lumpy Like a sausage or but snake but with cracks on its surface Sausage-shaped lumpy Like a sausage 2 orbut snake but with cracks on Sausage-shaped but its lumpy Like a sausage or snake but with cracks on its surface surface Sausage-shaped lumpy Like a sausage orbut snake but with cracks on its surface sausage oron snake Like a sausage or snake Like but awith cracks its but 3 surface with cracks its surface Like a sausage or snake, smooth andon soft Like a sausage or snake but with cracks on its Like a sausage or snake, smooth and soft surface Like a sausage or snake, smooth and soft Like a sausage or snake but with cracks on its Like a sausage or snake, surface Like a sausage 4 or snake, smooth and soft
smooth and soft
Like a sausage or snake, smooth and soft
Soft blobs blobs with with clear-cut clear-cut edges edges Soft
Like a sausage or snake, smooth and soft Soft blobs with 5 clear-cut edges Soft blobs with clear-cut edges
Fluffy pieces with ragged edges edges, a mushy stool Soft blobs with clear-cut
Fluffy pieces with ragged edges, a mushy stool
Fluffy pieces with 6 ragged edges, a mushy stool
Soft blobs with clear-cut edges Fluffy pieces with ragged edges, a mushy stool Soft blobs with clear-cut edges Fluffy pieces with ragged edges, a mushy stool
Watery, no solid7 pieces
Watery, no solid pieces
Fluffy pieces with ragged edges, a mushy stool Watery, no solid pieces Fluffy pieces with ragged edges, a mushy stool
withWatery, permission Lewis SJ, Heaton KW, Scandinavian Journal of Gastroenterology, 1997; 32(9):920–924. nofrom solid pieces »» http://bowelcontrol.nih.gov/Bristol_Stool_Form_Scale_508.pdf Healthcare.
Heaton KW. ScandaJ Gastroenterol. 1997;32(9):920–924. Fluffy piecesLewis withSJ,ragged edges, mushy stool
nofrom solid pieces withWatery, permission Lewis SJ, Heaton KW, Scandinavian Journal of Gastroenterology, 1997; 32(9):920–924. Healthcare.
nofrom solid pieces d withWatery, permission Lewis SJ, CME Heaton KW, Scandinavian Journal of Gastroenterology, 1997; 32(9):920–924. 23 For additional activities log on to Healthcare.
RESOURCE CENTER
Like a sausage or snake, smooth and soft Soft blobs with clear-cut edges
NOTES
24
CLINICAL ASSESSMENT TOOLS Bowel Function Index Please answer the following three questions by making a mark on the line between 0 and 100. Please transfer the results to the open squares at the bottom of the page. Add the three results and divide by three.
Question 1 (Q1) How would you rate the ease of defecation during the last 7 days according to patient assessment? 0=Easy/no difficulty
50
100=Severe difficulty
Question 2 (Q2) Does your patient feel that his/her bowel evacuation has been incomplete during the last 7 days? 0=Not at all
50
100=Very strongly
Question 3 (Q3) How would you judge your patient’s constipation throughout the last 7 days? 50
100=Very heavily constipated
RESOURCE CENTER
0=No constipation at all
Results Q1
Q2
+
Q3
+
Sum
=
Total
/3=
Adapted from Rentz AM, et al. J Med Econ. 2009;12(0):371-383.
For additional CME activities log on to
25
NOTES
26
CLINICAL ASSESSMENT TOOLS »» Patient Assessment of Constipation (PAC-SYM) This 12-item questionnaire of patient-reported symptoms assesses 3 subscales of symptoms (bowel movements, rectal symptoms, and abdominal symptoms) over the prior 2 weeks. www.proqolid.org/content/download/11747/176511/version/2/ file/PAC-SYM12_2.1_eng-US_review+copy.pdf
PATIENT RESOURCES »» Patient Conversation Guide This patient tool can be completed prior to the visit with the health care provider to guide a meaningful conversation about bowel habits and constipation symptoms. www.theacpa.org/uploads/ACPA-Opioid_Constipation_Chart-V4.pdf
»» Patient Education Handout This leaflet provides patients with approaches to mitigate opioidinduced constipation and includes a list of questions about constipation for patients to ask their doctors or clinics. www.acponline.org/patients_families/products/health_tips/oic_en.pdf
PRACTICE GUIDELINES »» The Functional Gastrointestinal Disorders and the Rome III Process, 2006. Drossman DA. Gastroenterology. 2006;130(5):1377-1390. www.ncbi.nlm.nih.gov/pubmed/16678553
RESOURCE CENTER
»» Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain, 2009. Chou R, et al. J Pain. 2009;10(2):113-130. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4043401/
»» VA/DoD Clinical Practice Guideline: Management of Opioid Therapy for Chronic Pain, 2010. Department of Veterans Affairs, Department of Defense. www.healthquality.va.gov/guidelines/Pain/cot/COT_312_Full-er.pdf
For additional CME activities log on to
27
OTHER RESOURCES »» A Clinical Guide to Opioid Analgesia. 2nd edition. Fine PG, Portenoy RK. New York, NY: Vendome Group, LLC; 2007. www.amazon.com/A-Clinical-Guide-Opioid-Analgesia/dp/1933692626#
»» Responsible Opioid Prescribing: A Clinician’s Guide. 2nd edition, revised and expanded. Fishman SM. Washington, DC: Waterford Life Sciences; 2012. library.fsmb.org/cme/index.html
SUGGESTED READING »» Opioid-induced bowel dysfunction: epidemiology, pathophysiology, diagnosis, and initial therapeutic approach. Dorn S, et al. Am J Gastroenterol. 2014;2(1):31-37.
»» Opioid-induced constipation in patients with chronic noncancer pain in the USA, Canada, Germany, and the UK: descriptive analysis of baseline patient-reported outcomes and retrospective chart review. Coyne KS, et al. Clinicoecon Outcomes Res. 2014;6:269-281.
»» Constipation in people prescribed opioids. Ahmedzai SH, Boland J. BMJ Clin Evid (Online). 2010;pii:2407.
»» The narcotic bowel syndrome: a recent update. Drossman D, Szigethy E. Am J Gastroenterol. 2014;2(1):22-30.
RESOURCE CENTER
»» Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Kalso E, et al. Pain. 2004;112(3):372-380.
»» A multi-institutional study analyzing effect of prophylactic medication for prevention of opioid-induced gastrointestinal dysfunction. Ishihara M, et al. Clin J Pain. 2012;28(5):373-381.
»» A volunteer model for the comparison of laxatives in opioid-related constipation. Sykes NP. J Pain Symptom Manage. 1996;11(6):363-369.
28
»» Establishing “best practices” for opioid rotation: conclusions of an expert panel. Fine PG, et al. J Pain Symptom Manage. 2009;38(3):418-425.
»» Naloxegol for opioid-induced constipation in patients with noncancer pain. Chey WD, et al. N Engl J Med. 2014;370(25):2387-2396.
»» A randomized study of lubiprostone for opioid-induced constipation in patients with chronic noncancer pain. Cryer B, et al. Pain Med. 2014; 15(11):1825-1834.
»» Clinical evaluation of the efficacy of methylnaltrexone in resolving constipation induced by different opioid subtypes combined with laboratory analysis of immunomodulatory and antiangiogenic effects of methylnaltrexone. Neefjes ECW, et al. BMC Palliative Care. 2014;13:42.
»» Patient preference with respect to QoL and reduction in opioid-induced constipation after treatment with prolonged-release oxycodone/naloxone compared with previous analgesic therapy [PREFER study].
RESOURCE CENTER
van Dongen VCPC, et al. Int J Clin Pract. 2014;68(11):1364-1375.
For additional CME activities log on to
29
NOTES
30
Please visit the CLINICAL RESOURCE CENTER for additional information and resources
www.EXCHANGECME.com/OICPCP2015
Š 2015 Global Education Group and Integritas Communications. All rights reserved. No part of this syllabus may be used or reproduced in any manner whatsoever without written permission except in the case of brief quotations embedded in articles or reviews.